Associated Papers
Synchronous diagnosis of multicentric glioma with distinct isocitrate dehydrogenase molecular profiles: a case report.
Mohan AA et al.
Cns Oncology, 2026
A Case of IDH-Mutant Astrocytoma Harboring an IDH2 R172_H173delinsSN Variant.
Auen T et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology, 2026
Oncometabolite D-2-hydroxyglutarate regulates actin dynamics and nuclear homeostasis in IDH1-mutant glioma.
Lathoria K et al.
Cellular Signalling, 2026
Portable duplex digital PCR for on-site detection of IDH mutations in gliomas.
Jung D et al.
Biosensors & Bioelectronics, 2026
SMARCA4 deficiency in glioblastoma: Mitochondrial transfer from MSCs and the clinical dilemma in targeting the tumor microenvironment.
Yang F et al.
Neoplasia (new York, N.y.), 2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K et al.
Acta Neuropathologica, 2026
From Diagnosis Delay to Targeted Therapy: A Retrospective Study of Pediatric DLGNT with a Comprehensive Literature Review.
De Carli R et al.
Cancers, 2026
Gliomas with succinate dehydrogenase deficiency: A case series and brief review of the literature of oncometabolite-driven gliomagenesis.
Gray MT et al.
Journal of Neuropathology and Experimental Neurology, 2026
IDH-mutant inhibitors enhance the sensitivity of IDH1-mutant gliomas to cysteine-methionine deprivation and ferroptosis.
Mela A et al.
Biorxiv : the Preprint Server for Biology, 2026
Using the Reactome Graph Database to generate pathway fingerprints for cancer-related genes, and using the fingerprints to gain insights into cancer, comorbidity, and cancer gene networks.
Iengar P et al.
Computational Biology and Chemistry, 2026
Zinc Protoporphyrin Functions as a Ferroptosis Inducer to Activate Heme-BACH Axis and Potently Suppress IDH1-Mutant Gliomas.
Yang Y et al.
Antioxidants & Redox Signaling, 2026
Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.
Dai Q et al.
Chemistry & Biodiversity, 2026
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial.
Jones RL et al.
Nature Communications, 2026
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML.
Jia A et al.
Cell Metabolism, 2026
FAS rs2234767 polymorphism confers protection against glioma: a case-control study in Chinese population.
Huang X et al.
The International Journal of Neuroscience, 2026
Redefining Treatment Paradigms for Glioma in Adolescents and Young Adults: Population-Based Evidence for Molecular Classification.
Qu S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotype.
Stasik S et al.
Annals of Hematology, 2026
Diffuse low-grade glioma with a rare BRAF p.T599dup mutation in a child: importance of clinicopathological and molecular correlation.
Yamada S et al.
Brain Tumor Pathology, 2026
Evaluation of the Idylla IDH1-2 Mutation Assay for the Detection of IDH Variants in Solid Tumors and Hematological Malignancies.
Gilson P et al.
International Journal of Molecular Sciences, 2026
Germline variants in ATM, BRCA2, other cancer predisposition and novel candidate genes are implicated in glioma risk in adult glioma patients with a familial or personal history of tumors.
Brand F et al.
Acta Neuropathologica, 2026
KMT2A is a prerequisite of malignant transformation during IDH-mutant gliomagenesis.
Koch MS et al.
Neuro-oncology, 2026
Autopalmitoylation of IDH1-R132H regulates its neomorphic activity in cancer cells.
Hu L et al.
Nature Chemical Biology, 2026
Diffuse leptomeningeal glioneuronal tumor in an adult male without leptomeningeal enhancement: The diagnostic value of integrated molecular profiling.
Walsh LM et al.
Journal of Neuropathology and Experimental Neurology, 2026
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation.
Park JW et al.
Science (new York, N.y.), 2026
Distal noncontiguous recurrence and sarcomatous transformation of glioblastoma with stable molecular profile: illustrative case.
Howran J et al.
Journal of Neurosurgery. Case Lessons, 2026
A Case of a Fumarate Hydratase Deficient Astrocytoma in Association With a Germline Fumarate Hydratase Mutation With Review of the Literature: Considerations for Patients With Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Syndrome.
Alfattal R et al.
The American Journal of Surgical Pathology, 2026
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma.
Fernandez NR et al.
Nature Genetics, 2026
Mutation patterns drive mismatch repair-deficient glioma evolution.
Unknown Author
Nature Genetics, 2026
Current Perspectives on Pediatric Low-Grade Gliomas: Focus on BRAF and MEK Inhibition.
Suh JK et al.
Brain Tumor Research and Treatment, 2026
Comprehensive Genomic Profiling Across Diverse Solid Tumors: A Real-World Experience From India With FoundationOne®CDx Testing.
Julka PK et al.
Cureus, 2026
Clonal hematopoiesis associates with prevalent and incident cardiometabolic disease in a cardiac catheterization cohort.
Regan JA et al.
Plos One, 2026
KRTCAP2 accelerates malignant progression through modulating tumor cell function and M2 macrophage infiltration in glioma.
Zhao C et al.
Frontiers in Immunology, 2026
SOMATIC GENE VARIANTS IN UNRESECTABLE CUTANEOUS MELANOMA CELLS AND DETECTION OF PHARMACOGENOMIC MARKERS: INFLUENCE ON STRATEGY OF EFFECTIVE CANCER TREATMENT.
Gulkovskyi R et al.
Experimental Oncology, 2025
MAPK Pathway Mutations Emerge in Mutant-IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the Interferon Response.
Wan J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Tall cell carcinoma with reversed polarity of the breast harbouring IDH1 hotspot mutation: morphologic, immunohistochemical and genetic characterization of two cases.
Krings G et al.
Histopathology, 2025
Precision Oncology for Pediatric Solid Tumors Using In-Hospital Pediatric/AYA Malignancy-Specific Panel Sequencing.
Kojima M et al.
Cancer Science, 2025
Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies.
Xu W et al.
The Oncologist, 2025
Molecular Characterization of Adult-Type Lower-Grade Glioma (WHO Grade 1-3) with Targeted Next-Generation Sequencing: A Retrospective, Single-Institution Experience.
Pinamonti M et al.
Journal of Clinical Medicine, 2025
Glioblastoma-A Contemporary Overview of Epidemiology, Classification, Pathogenesis, Diagnosis, and Treatment: A Review Article.
Królikowska K et al.
International Journal of Molecular Sciences, 2025
Clonal architecture of FLT3-ITD and acquired 13q uniparental disomy define prognostic heterogeneity and therapeutic vulnerabilities in acute myeloid leukemia.
Lai A et al.
Neoplasia (new York, N.y.), 2025
Integrative machine learning-guided in silico and in vitro approach reveals selective small molecule inhibitors targeting mutant IDH1.
Bajaj M et al.
Rsc Advances, 2025
Widespread Epistasis between Cancer Driver Mutations and Allele-Specific Copy Number Variations.
Merzliakov S et al.
Biorxiv : the Preprint Server for Biology, 2025
A Primary CNS Sarcoma of the Spinal Cord with DICER1 Mutation: Expanding the Spectrum of DICER1-Driven CNS Sarcomas.
Pasarikovski CR et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques, 2025
Ultrasensitive Detection of Rare Mutations via Amplifying-Cleaving-Enriching in Acute Myeloid Leukemia.
Zhuang X et al.
Biomedicines, 2025
Nucleotide Substitution Biases in Related Cancer Driver Genes.
Khadre A et al.
International Journal of Molecular Sciences, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With Olutasidenib.
Chien KS et al.
Clinical Lymphoma, Myeloma & Leukemia, 2025
Fumarate hydratase-mutant glioma with giant-cell histology, MSH6 mutation, and hypermutation.
Mafficini A et al.
Journal of Neuropathology and Experimental Neurology, 2025